$KRYS News

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome

Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders

Why Krystal Biotech (KRYS) Is Drawing Fresh Attention

Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run

$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today

Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference